|
| |
NextGen Sciences Appoints New CEO and Expands
Service Offering to Include Protein Biomarker Monitoring
Cambridgeshire, UK, 09 November 2007 – NextGen
Sciences, a leading provider of gene-to-protein products and services, has
appointed Dr Mike Pisano as CEO, and has announced the expansion of its
portfolio of services to include clinical protein biomarker monitoring.
As recently announced, Dr Pisano joins the Company from Proteomic Research
Services (PRS), which was acquired by the NextGen Group in November 2006, where
he was cofounder and CEO. With over a decade of senior management experience in
the pharmaceutical industry, Dr Pisano’s previous roles include Group Leader,
Proteomics and Protein Production, Rhone-Poulenc Rorer Pharmaceuticals; Head,
Protein Sciences, Aventis Pharmaceuticals; and Vice-President Proteomic R&D,
Genomic Solutions, Inc. Dr. Pisano currently serves on the Scientific Advisory
Board of several life sciences companies and instrumentation manufacturers.
The new protein biomarker services from NextGen Sciences include:
- Assay development and validation
- Monitoring and verification of protein biomarkers
from pre-clinical and clinical samples
- Identification of putative protein biomarkers and
proteins of interest
The new biomarker services are underpinned by the
Company’s core expertise in protein science, as well as investment in leading
technologies such as the OrbiTrap and triple quad mass spectrometers from
ThermoFisher. Integration of these technologies with the mass spectrometry-based
technique of Multiple Reaction Monitoring (MRM) has enabled the Company to
develop a high throughput platform for rapid and highly specific biomarker
validation. NextGen Sciences is already working on a number of clinical
biomarker projects in partnership with major pharmaceutical companies.
Commenting on the new services, Dr. Pisano said: “Our investment in leading
technologies, in combination with the expertise of our scientists, enables us to
offer customers the best possible services for clinical biomarker discovery and
development programs. We are already working with a number of major customers to
develop robust, accurate and precise assays to meet the needs of their clinical
biomarker projects. Through the acquisition of PRS and also in partnership with
Kemp Biotechnologies, we can now offer our customers the most comprehensive
range of products and services, which can be tailored to meet individual
requirements for successful customer projects.”
- ENDS -
For a high resolution image please contact Northbank Communications
Contact
NextGen Sciences
Grant Cameron
t: +44 (0)1480 420970
e:
grant.cameron@nextgensciences.com
Northbank Communications
Ben Routley and Katie Odgaard
t: +44 (0)1260 296 500/+44 (0)207 268 3002
e:
nextgen@northbankcommunications.com
Notes to Editors:
About NextGen Group PLC
NextGen Group PLC (LSE:NGG) offers its customers a comprehensive range of
enabling technologies, services and expertise to improve their chance of success
in protein science research. Working in partnership with 18 of the top 20
pharmaceutical companies, the Company’s products and services cover the gene to
protein continuum. The Company has developed a wide range of leading automation
platforms and integrated software systems that have been proven to enhance the
productivity and efficiency of customers’ research programs. The services range
from gene synthesis to protein expression scale-up and purification, protein
analytical services, protein biomarker discovery and monitoring.
The breadth of services has been enhanced through key strategic partnerships
with Gene Oracle, Inc., for gene optimization and synthesis, and Kemp
Biotechnologies, Inc., for protein expression scale up, cell culture and protein
purification.
Further details relating to NextGen Group PLC and its products can be found at
www.nextgensciences.com
| |
|
